Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers

Ranee Mehra, Fang Zhu, Dong Hua Yang, Kathy Q. Cai, Joellen Weaver, Mahendra Singh, Anna S. Nikonova, Erica A. Golemis, Douglas B. Flieder, Harry S. Cooper, Miriam Lango, John A. Ridge, Barbara Burtness

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: Multimodality treatment of squamous cell carcinoma of the head and neck (SCCHN) often involves radiotherapy and cisplatin-based therapy. Elevated activity of DNA repair mechanisms, such as the nucleotide excision repair (NER) pathway, of which ERCC1 is a rate-limiting element, are associated with cisplatin and possibly RT resistance. We have determined excision repair cross-complementing group 1 (ERCC1) expression in human papillomavirus (HPV)-negative SCCHN treated with surgery [±adjuvant radiotherapy/ chemoradiation (CRT)]. Experimental Design: We assessed ERCC1 protein expression in archival tumors using immunofluorescence staining and automatic quantitative analysis (AQUA) with three antibodies to ERCC1 (8F1, FL297, and HPA029773). Analysis with Classification and Regression Tree (CART) methods ascertained the cutoff points between high/low ERCC1 expression. Multivariable analysis adjusted for age, T, and N stage. Kaplan-Meier curves determined median survival. ERCC1 expression at initial tumor presentation and in recurrent disease were compared. Performance characteristics of antibodies were assessed. Results: ERCC1 low/high groups were defined on the basis of AQUA analysis with 8F1/2009, FL297, and HPA029773. Among patients treated with surgeryplus adjuvant radiotherapy/CRT, longer median survival was observed in ERCC1-low versus ERCC1-high tumors (64 vs. 29 months; P - 0.02; HPA029773). Data obtained with HPA029773 indicated no survival difference among patients treated only with surgery. Recurrent cancers had lower ERCC1 AQUA scores than tumors from initial presentation. Extensive characterization indicated optimal specificity and performance by the HPA029773 antibody. Conclusions: Using AQUA, with the specific ERCC1 antibody HPA029773, we found a statistical difference in survival among high/low-ERCC1 tumors from patients treated with surgery and adjuvant radiotherapy.

Original languageEnglish (US)
Pages (from-to)6633-6643
Number of pages11
JournalClinical Cancer Research
Volume19
Issue number23
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Squamous Cell Neoplasms
Head and Neck Neoplasms
DNA Repair
Survival
Adjuvant Radiotherapy
Neoplasms
Antibodies
Cisplatin
Fluorescent Antibody Technique

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. / Mehra, Ranee; Zhu, Fang; Yang, Dong Hua; Cai, Kathy Q.; Weaver, Joellen; Singh, Mahendra; Nikonova, Anna S.; Golemis, Erica A.; Flieder, Douglas B.; Cooper, Harry S.; Lango, Miriam; Ridge, John A.; Burtness, Barbara.

In: Clinical Cancer Research, Vol. 19, No. 23, 01.12.2013, p. 6633-6643.

Research output: Contribution to journalArticle

Mehra, R, Zhu, F, Yang, DH, Cai, KQ, Weaver, J, Singh, M, Nikonova, AS, Golemis, EA, Flieder, DB, Cooper, HS, Lango, M, Ridge, JA & Burtness, B 2013, 'Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers', Clinical Cancer Research, vol. 19, no. 23, pp. 6633-6643. https://doi.org/10.1158/1078-0432.CCR-13-0152
Mehra, Ranee ; Zhu, Fang ; Yang, Dong Hua ; Cai, Kathy Q. ; Weaver, Joellen ; Singh, Mahendra ; Nikonova, Anna S. ; Golemis, Erica A. ; Flieder, Douglas B. ; Cooper, Harry S. ; Lango, Miriam ; Ridge, John A. ; Burtness, Barbara. / Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 23. pp. 6633-6643.
@article{dd8f7727311d4677b87c1a7123a720fd,
title = "Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers",
abstract = "Purpose: Multimodality treatment of squamous cell carcinoma of the head and neck (SCCHN) often involves radiotherapy and cisplatin-based therapy. Elevated activity of DNA repair mechanisms, such as the nucleotide excision repair (NER) pathway, of which ERCC1 is a rate-limiting element, are associated with cisplatin and possibly RT resistance. We have determined excision repair cross-complementing group 1 (ERCC1) expression in human papillomavirus (HPV)-negative SCCHN treated with surgery [±adjuvant radiotherapy/ chemoradiation (CRT)]. Experimental Design: We assessed ERCC1 protein expression in archival tumors using immunofluorescence staining and automatic quantitative analysis (AQUA) with three antibodies to ERCC1 (8F1, FL297, and HPA029773). Analysis with Classification and Regression Tree (CART) methods ascertained the cutoff points between high/low ERCC1 expression. Multivariable analysis adjusted for age, T, and N stage. Kaplan-Meier curves determined median survival. ERCC1 expression at initial tumor presentation and in recurrent disease were compared. Performance characteristics of antibodies were assessed. Results: ERCC1 low/high groups were defined on the basis of AQUA analysis with 8F1/2009, FL297, and HPA029773. Among patients treated with surgeryplus adjuvant radiotherapy/CRT, longer median survival was observed in ERCC1-low versus ERCC1-high tumors (64 vs. 29 months; P - 0.02; HPA029773). Data obtained with HPA029773 indicated no survival difference among patients treated only with surgery. Recurrent cancers had lower ERCC1 AQUA scores than tumors from initial presentation. Extensive characterization indicated optimal specificity and performance by the HPA029773 antibody. Conclusions: Using AQUA, with the specific ERCC1 antibody HPA029773, we found a statistical difference in survival among high/low-ERCC1 tumors from patients treated with surgery and adjuvant radiotherapy.",
author = "Ranee Mehra and Fang Zhu and Yang, {Dong Hua} and Cai, {Kathy Q.} and Joellen Weaver and Mahendra Singh and Nikonova, {Anna S.} and Golemis, {Erica A.} and Flieder, {Douglas B.} and Cooper, {Harry S.} and Miriam Lango and Ridge, {John A.} and Barbara Burtness",
year = "2013",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-13-0152",
language = "English (US)",
volume = "19",
pages = "6633--6643",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers

AU - Mehra, Ranee

AU - Zhu, Fang

AU - Yang, Dong Hua

AU - Cai, Kathy Q.

AU - Weaver, Joellen

AU - Singh, Mahendra

AU - Nikonova, Anna S.

AU - Golemis, Erica A.

AU - Flieder, Douglas B.

AU - Cooper, Harry S.

AU - Lango, Miriam

AU - Ridge, John A.

AU - Burtness, Barbara

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Purpose: Multimodality treatment of squamous cell carcinoma of the head and neck (SCCHN) often involves radiotherapy and cisplatin-based therapy. Elevated activity of DNA repair mechanisms, such as the nucleotide excision repair (NER) pathway, of which ERCC1 is a rate-limiting element, are associated with cisplatin and possibly RT resistance. We have determined excision repair cross-complementing group 1 (ERCC1) expression in human papillomavirus (HPV)-negative SCCHN treated with surgery [±adjuvant radiotherapy/ chemoradiation (CRT)]. Experimental Design: We assessed ERCC1 protein expression in archival tumors using immunofluorescence staining and automatic quantitative analysis (AQUA) with three antibodies to ERCC1 (8F1, FL297, and HPA029773). Analysis with Classification and Regression Tree (CART) methods ascertained the cutoff points between high/low ERCC1 expression. Multivariable analysis adjusted for age, T, and N stage. Kaplan-Meier curves determined median survival. ERCC1 expression at initial tumor presentation and in recurrent disease were compared. Performance characteristics of antibodies were assessed. Results: ERCC1 low/high groups were defined on the basis of AQUA analysis with 8F1/2009, FL297, and HPA029773. Among patients treated with surgeryplus adjuvant radiotherapy/CRT, longer median survival was observed in ERCC1-low versus ERCC1-high tumors (64 vs. 29 months; P - 0.02; HPA029773). Data obtained with HPA029773 indicated no survival difference among patients treated only with surgery. Recurrent cancers had lower ERCC1 AQUA scores than tumors from initial presentation. Extensive characterization indicated optimal specificity and performance by the HPA029773 antibody. Conclusions: Using AQUA, with the specific ERCC1 antibody HPA029773, we found a statistical difference in survival among high/low-ERCC1 tumors from patients treated with surgery and adjuvant radiotherapy.

AB - Purpose: Multimodality treatment of squamous cell carcinoma of the head and neck (SCCHN) often involves radiotherapy and cisplatin-based therapy. Elevated activity of DNA repair mechanisms, such as the nucleotide excision repair (NER) pathway, of which ERCC1 is a rate-limiting element, are associated with cisplatin and possibly RT resistance. We have determined excision repair cross-complementing group 1 (ERCC1) expression in human papillomavirus (HPV)-negative SCCHN treated with surgery [±adjuvant radiotherapy/ chemoradiation (CRT)]. Experimental Design: We assessed ERCC1 protein expression in archival tumors using immunofluorescence staining and automatic quantitative analysis (AQUA) with three antibodies to ERCC1 (8F1, FL297, and HPA029773). Analysis with Classification and Regression Tree (CART) methods ascertained the cutoff points between high/low ERCC1 expression. Multivariable analysis adjusted for age, T, and N stage. Kaplan-Meier curves determined median survival. ERCC1 expression at initial tumor presentation and in recurrent disease were compared. Performance characteristics of antibodies were assessed. Results: ERCC1 low/high groups were defined on the basis of AQUA analysis with 8F1/2009, FL297, and HPA029773. Among patients treated with surgeryplus adjuvant radiotherapy/CRT, longer median survival was observed in ERCC1-low versus ERCC1-high tumors (64 vs. 29 months; P - 0.02; HPA029773). Data obtained with HPA029773 indicated no survival difference among patients treated only with surgery. Recurrent cancers had lower ERCC1 AQUA scores than tumors from initial presentation. Extensive characterization indicated optimal specificity and performance by the HPA029773 antibody. Conclusions: Using AQUA, with the specific ERCC1 antibody HPA029773, we found a statistical difference in survival among high/low-ERCC1 tumors from patients treated with surgery and adjuvant radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84890297022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890297022&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-0152

DO - 10.1158/1078-0432.CCR-13-0152

M3 - Article

VL - 19

SP - 6633

EP - 6643

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -